San Francisco-based Rigel Pharmaceuticals on Thursday announced it will acquire the U.S. rights to Blueprint Medicines’ FDA-approved non-small cell lung cancer drug Gavreto (pralsetinib).
Tag Archive for: Rigel
Ten months after taking over a state-of-the-art facility in New York that was expected to expand the company’s manufacturing footprint, ImmunityBio announced job cuts at the site.
